Malignancy after Pediatric Kidney Transplantation: The 30-Year Experience of a Single Center
1
조회
0
다운로드
0
인용
0
참고문헌
키워드
초록
Objectives: We aimed to investigate the incidence, manifestations, and outcomes of malignancy after pediatric kidney transplantation (KT) at our center over 30 years. Methods: We retrospectively reviewed the medical records of 155 patients under 18 years of age who underwent KT between January 1990 and February 2020 at Asan Medical Center. Results: Twelve patients (7.7%) were diagnosed with a malignancy after KT. Malignancy was diagnosed after a mean period of 6.4±5.9 years (median 4.6, range 0.5–20.6 years) after KT. Nine (75.0%) of the 12 cancer patients were diagnosed with post-transplant lymphoproliferative disease (PTLD), and the other three had papillary thyroid cancer, mucoepidermoid cancer of the hard palate, and T-cell acute lymphoblastic leukemia, respectively. PTLD was diagnosed within a mean of 3.7±3.4 years (median 3.7, range 0.5–9.8 years) after KT. Five patients diagnosed with PTLD were cured without recurrence. Three patients with PTLD died from the disease, and one patient with mucoepidermoid cancer from a non-PTLD malignancy died after progression, despite surgical resection and chemotherapy. Three (33.3%) of the nine survivors progressed to end-stage renal disease (ESRD) after completing cancer treatment. No patient with post-transplant malignancy (PTM) experienced critical renal deterioration during cancer treatment. Conclusion: PTLD was the most common PTM, occurring at 5.8% of the pediatric KT patients after KT in our center. Careful follow up is needed particularly considering the risk of PTLD after KT in children.
Abstract
Objectives: We aimed to investigate the incidence, manifestations, and outcomes of malignancy after pediatric kidney transplantation (KT) at our center over 30 years. Methods: We retrospectively reviewed the medical records of 155 patients under 18 years of age who underwent KT between January 1990 and February 2020 at Asan Medical Center. Results: Twelve patients (7.7%) were diagnosed with a malignancy after KT. Malignancy was diagnosed after a mean period of 6.4±5.9 years (median 4.6, range 0.5–20.6 years) after KT. Nine (75.0%) of the 12 cancer patients were diagnosed with post-transplant lymphoproliferative disease (PTLD), and the other three had papillary thyroid cancer, mucoepidermoid cancer of the hard palate, and T-cell acute lymphoblastic leukemia, respectively. PTLD was diagnosed within a mean of 3.7±3.4 years (median 3.7, range 0.5–9.8 years) after KT. Five patients diagnosed with PTLD were cured without recurrence. Three patients with PTLD died from the disease, and one patient with mucoepidermoid cancer from a non-PTLD malignancy died after progression, despite surgical resection and chemotherapy. Three (33.3%) of the nine survivors progressed to end-stage renal disease (ESRD) after completing cancer treatment. No patient with post-transplant malignancy (PTM) experienced critical renal deterioration during cancer treatment. Conclusion: PTLD was the most common PTM, occurring at 5.8% of the pediatric KT patients after KT in our center. Careful follow up is needed particularly considering the risk of PTLD after KT in children.
참고문헌 (23)
- "Annual national data repot from KONOS transplantation analysis"[URL]
- Samuel SM, "Survival in pediatric dialysis and transplant patients", Clin J Am Soc Nephrol, 6, pp.1094~1099 (2011)
- Koukourgianni F, "Malignancy incidence after renal transplantation in children : a 20-year single-centre experience", Nephrol Dial Transplant, 25, pp.611~616 (2010)
- Kim JH, , 49th European Renal Association-European dialysis and Transplant association Congress, Transplantation session: 502, 94, pp.847~ (2012)
- Heo J, "Cancer risk after renal transplantation in South Korea : a nationwide population-based study", BMC Nephrol, 19, pp.311~ (2018)
- Serrano OK, "Post-Transplant Malignancy after Pediatric Kidney Transplantation : Retrospective Analysis of Incidence and Risk Factors in 884 Patients Receiving Transplants Between 1963 and 2015 at the University of Minnesota", J Am Coll Surg, 225, pp.181~193 (2017)
- You J, "Epstein-Barr virus infection in children with renal transplantation : A single-centre experience", Nephrology, 23, pp.1039~1045 (2018)
- Dharnidharka VR, "Post-transplant lymphoproliferative disease", Pediatr Nephrol, 24, pp.731~736 (2009)
- Al-Mansour Z, "Post-transplant lymphoproliferative disease (PTLD): risk factors, diagnosis, and current treatment strategies", Curr Hematol Malig Rep, 8, pp.173~183 (2013)
- Schwartz GJ, "New equations to estimate GFR in children with CKD", J Am Soc Nephrol, 20, pp.629~637 (2009)
- Kwon H, "Analysis of 4000 kidney transplantations in a single center : Across immunological barriers", Medicine, 95, pp.e4249~ (2016)
- 정형주, "Posttransplantation lymphoproliferative disorder after pediatric solid organ transplantation: experiences of 20 years in a single center", Clinical and Experimental Pediatrics, 60(3), pp.86~93 (2017), 대한소아청소년과학회
- 현혜선, "Post-Transplant Lymphoproliferative Diseases in Pediatric Kidney Allograft Recipients with Epstein-Barr Virus Viremia", Journal of Korean Medical Science, 34(30), pp.1~13 (2019), 대한의학회
- Opelz G, "Lymphomas after solid organ transplantation : a collaborative transplant study report", Am J Transplant, 4, pp.222~230 (2004)
- Schober T, "Characteristics of Early and Late PTLD Development in Pediatric Solid Organ Transplant Recipients", Transplantation, 95 (2013)
- Mynarek M, "Malignancies after pediatric kidney transplantation : more than PTLD?", Pediatr Nephrol, 29, pp.1517~1528 (2014)
- Parker A, "Diagnosis of post-transplant lymphoproliferative disorder in solid organ transplant recipients-BCSH and BTS Guidelines", Br J Haematol, 149, pp.675~692 (2010)
- Opelz G, "Epidemiology of pretransplant EBV and CMV serostatus in relation to posttransplant non-Hodgkin lymphoma", Transplantation, 88, pp.962~967 (2009)
- Opelz G, "Pediatric kidney transplantation: analysis of donor age, HLA match, and posttransplant non-Hodgkin lymphoma:a collaborative transplant study report", Transplantation, 90, pp.292~297 (2010)
- Lustberg ME, "Human leukocyte antigen type and posttransplant lymphoproliferative disorder", Transplantation, 99, pp.1220~1225 (2015)
- Pascual J, "Post-transplant lymphoproliferative disorder--the potential of proliferation signal inhibitors", Nephrol Dial Transplant, 22(Suppl 1), pp.i27~35 (2007)
- McDonald RA, "Incidence of PTLD in Pediatric Renal Transplant Recipients Receiving Basiliximab, Calcineurin Inhibitor, Sirolimus and Steroids", Am J Transplant, 8, pp.984~989 (2008)
- Francis A, "Posttransplant lymphoproliferative disease may be an adverse risk factor for patient survival but not graft loss in kidney transplant recipients", Kidney Int, 94, pp.809~817 (2018)